Nicholas Galakatos - Net Worth and Insider Trading

Nicholas Galakatos Net Worth

The estimated net worth of Nicholas Galakatos is at least $7 Million dollars as of 2024-04-25. Nicholas Galakatos is the Director, 10% Owner of Entasis Therapeutics Holdings Inc and owns about 1,623,405 shares of Entasis Therapeutics Holdings Inc (ETTX) stock worth over $4 Million. Nicholas Galakatos is the 10% Owner of Rigel Pharmaceuticals Inc and owns about 1,833,597 shares of Rigel Pharmaceuticals Inc (RIGL) stock worth over $2 Million. Nicholas Galakatos is also the Director, 10% Owner of NanoString Technologies Inc and owns about 4,036,025 shares of NanoString Technologies Inc (NSTGQ) stock worth over $1 Million. Besides these, Nicholas Galakatos also holds Astria Therapeutics Inc (ATXS) , IVERIC bio Inc (ISEE) , Affymax Inc (AFFY) . Details can be seen in Nicholas Galakatos's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Nicholas Galakatos has not made any transactions after 2018-09-28 and currently still holds the listed stock(s).

Transaction Summary of Nicholas Galakatos

To

Nicholas Galakatos Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Nicholas Galakatos owns 28 companies in total, including Praxis Precision Medicines Inc (PRAX) , Entasis Therapeutics Holdings Inc (ETTX) , and NanoString Technologies Inc (NSTGQ) among others .

Click here to see the complete history of Nicholas Galakatos’s form 4 insider trades.

Insider Ownership Summary of Nicholas Galakatos

Ticker Comapny Transaction Date Type of Owner
PRAX Praxis Precision Medicines Inc 2020-10-15 director
ETTX Entasis Therapeutics Holdings Inc 2019-06-19 director
NSTGQ NanoString Technologies Inc 2018-09-17 director & 10 percent owner
FTSV Forty Seven Inc 2018-07-02 10 percent owner
VERO Venus Concept Inc 2017-10-11 10 percent owner
RDUS Radius Health Inc 2011-05-17 10 percent owner
ATXS Astria Therapeutics Inc 2015-06-30 director & 10 percent owner
TLOG TetraLogic Pharmaceuticals Corp 2016-02-08 10 percent owner
ISEE IVERIC bio Inc 2016-01-11 director & 10 percent owner
OXFD Oxford Immunotec Global PLC 2015-06-15 10 percent owner
AERI Aerie Pharmaceuticals Inc 2013-10-25 10 percent owner
SIENQ Sientra Inc 2014-10-28 10 percent owner
PTLA Portola Pharmaceuticals Inc 2014-06-27 director
GMED Globus Medical Inc 2012-08-02 other: Managing dir. of GP
HGENQ Humanigen Inc 2012-08-11 10 percent owner
ACHN Achillion Pharmaceuticals Inc 2012-06-04 10 percent owner
EPRSQ EPIRUS Biopharmaceuticals Inc 2011-10-27 10 percent owner
ZGNX Zogenix Inc 2011-09-16 10 percent owner
AVEO AVEO Pharmaceuticals Inc 2010-03-11 director & 10 percent owner
RSLS Reshape Lifesciences Inc 2010-12-14 other: Former 10% Owner
ALT Altimmune Inc 2007-08-03 other: See explanation below
ARYX ARYx Therapeutics Inc 2010-09-30 10 percent owner
LGNZZ Metabasis Therapeutics Inc 2010-01-27 10 percent owner
PARD Poniard Pharmaceuticals Inc 2009-11-05 10 percent owner
AFFY Affymax Inc 2009-05-28 director & 10 percent owner
RIGL Rigel Pharmaceuticals Inc 2004-07-02 10 percent owner
CYCC Cyclacel Pharmaceuticals Inc 2004-03-10 10 percent owner
TALS Talaris Therapeutics Inc 2021-05-06 director

Nicholas Galakatos Latest Holdings Summary

Nicholas Galakatos currently owns a total of 6 stocks. Among these stocks, Nicholas Galakatos owns 1,623,405 shares of Entasis Therapeutics Holdings Inc (ETTX) as of September 28, 2018, with a value of $4 Million and a weighting of 47.63%. Nicholas Galakatos owns 1,833,597 shares of Rigel Pharmaceuticals Inc (RIGL) as of July 2, 2004, with a value of $2 Million and a weighting of 26.53%. Nicholas Galakatos also owns 4,036,025 shares of NanoString Technologies Inc (NSTGQ) as of September 17, 2018, with a value of $1 Million and a weighting of 15.15%. The other 3 stocks Astria Therapeutics Inc (ATXS) , IVERIC bio Inc (ISEE) , Affymax Inc (AFFY) have a combined weighting of 10.69% among all his current holdings.

Latest Holdings of Nicholas Galakatos

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ETTX Entasis Therapeutics Holdings Inc 2018-09-28 1,623,405 2.19 3,555,257
RIGL Rigel Pharmaceuticals Inc 2004-07-02 1,833,597 1.08 1,980,285
NSTGQ NanoString Technologies Inc 2018-09-17 4,036,025 0.28 1,130,491
ATXS Astria Therapeutics Inc 2015-06-30 45,875 9.02 413,563
ISEE IVERIC bio Inc 2016-01-11 9,629 39.95 384,679
AFFY Affymax Inc 2006-12-14 49,998 0.00 35

Holding Weightings of Nicholas Galakatos


Nicholas Galakatos Form 4 Trading Tracker

According to the SEC Form 4 filings, Nicholas Galakatos has made a total of 0 transactions in Entasis Therapeutics Holdings Inc (ETTX) over the past 5 years. The most-recent trade in Entasis Therapeutics Holdings Inc is the acquisition of 453,395 shares on September 28, 2018, which cost Nicholas Galakatos around $7 Million.

According to the SEC Form 4 filings, Nicholas Galakatos has made a total of 0 transactions in Rigel Pharmaceuticals Inc (RIGL) over the past 5 years. The most-recent trade in Rigel Pharmaceuticals Inc is the sale of 1,652 shares on July 2, 2004, which brought Nicholas Galakatos around $25,325.

According to the SEC Form 4 filings, Nicholas Galakatos has made a total of 0 transactions in NanoString Technologies Inc (NSTGQ) over the past 5 years. The most-recent trade in NanoString Technologies Inc is the sale of 85,823 shares on September 17, 2018, which brought Nicholas Galakatos around $1 Million.

More details on Nicholas Galakatos's insider transactions can be found in the Insider Trading History of Nicholas Galakatos table.

Insider Trading History of Nicholas Galakatos

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Nicholas Galakatos Trading Performance

GuruFocus tracks the stock performance after each of Nicholas Galakatos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Nicholas Galakatos is -28.87%. GuruFocus also compares Nicholas Galakatos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Nicholas Galakatos within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Nicholas Galakatos's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Nicholas Galakatos

Average Return

-27.35%

Average return per transaction

Outperforming Transactions

33%

1 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -5.52 -28.87 -21.69 -27.35 -34.56 -24.3
Relative Return to S&P 500(%) -4.96 -24.82 -24.05 -34.23 -42.05 -35.22

Nicholas Galakatos Ownership Network

Ownership Network List of Nicholas Galakatos

No Data

Ownership Network Relation of Nicholas Galakatos


Nicholas Galakatos Owned Company Details

What does Praxis Precision Medicines Inc do?

Who are the key executives at Praxis Precision Medicines Inc?

Nicholas Galakatos is the director of Praxis Precision Medicines Inc. Other key executives at Praxis Precision Medicines Inc include Chief Executive Officer Marcio Souza , Chief Financial Officer Timothy Edwin Kelly , and Principal Accounting Officer Lauren Mastrocola .

Praxis Precision Medicines Inc (PRAX) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Praxis Precision Medicines Inc (PRAX). Other recent insider transactions involving Praxis Precision Medicines Inc (PRAX) include a net purchase of 80,002 shares made by Marcio Souza , a net purchase of 50,000 shares made by Dean J Mitchell , and a net purchase of 14,500 shares made by Jill Desimone .

In summary, during the past 3 months, insiders sold 0 shares of Praxis Precision Medicines Inc (PRAX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Praxis Precision Medicines Inc (PRAX) were sold and 10,167 shares were bought by its insiders, resulting in a net purchase of 10,167 shares.

Praxis Precision Medicines Inc (PRAX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Praxis Precision Medicines Inc Insider Transactions

No Available Data

Nicholas Galakatos Mailing Address

Above is the net worth, insider trading, and ownership report for Nicholas Galakatos. You might contact Nicholas Galakatos via mailing address: The John Hancock Tower, 200 Clarendon Street, 54th Floor, Boston Ma 02116.

Discussions on Nicholas Galakatos

No discussions yet.